Hepatitis C virus infection and its rheumatologic implications

Gastroenterology and Hepatology

Volumn 10, Issue 5, 2014, Pages 287-293

  Sayiner, Zeynel A ^a   Haque, Uzma ^a   Malik, Mohammad U ^a   Gurakar, Ahmet ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disease; Hepatitis C virus; Rheumatologic implication

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B CELL ACTIVATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSOME ANTIBODY; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; SM ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ANTIVIRAL THERAPY; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE EROSION; CLINICAL FEATURE; COMPLEMENT ACTIVATION; CRYOGLOBULINEMIA; CRYOPRECIPITATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOCOMPLEMENTEMIA; INTRAVENOUS DRUG ABUSE; JOINT BIOPSY; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYALGIA; OSTEOSCLEROSIS; PLASMAPHERESIS; POLYARTERITIS NODOSA; POLYARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; SUBCUTANEOUS NODULE; SYNOVIAL FLUID; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VIREMIA;

EID: 84902525621     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-362. (Pubitemid 19117877)
2. Ryan KJ, Ray CG, eds. Sherris Medical Microbiology. 4th ed. New York, NY: McGraw-Hill; 2004:551-552.
3. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J Hepatol. 2009;51(5):939-948.
4. Global alert and response (GAR). Hepatitis C. World Health Organization. www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html. Accessed March 27, 2014.
5. Hepatitis C FAQs for health professionals. Centers for Disease Control and Prevention. www.cdc.gov/hepatitis/HCV/HCVfaq.htm#section1. Accessed March 27, 2014.
6. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 2000;79(1):47-56. (Pubitemid 30077736)
7. Mohammed RH, ElMakhzangy HI, Gamal A, et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol. 2010;29(12):1373-1380.
8. Palazzi C, Olivieri I, Cacciatore P, Pennese E, D'Amico E. Difficulties in the differential diagnosis between primitive rheumatic diseases and hepatitis C virus-related disorders. Clin Exp Rheumatol. 2005;23(1):2-6. (Pubitemid 40424751)
9. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum. 1999;42(10):2204-2212. (Pubitemid 30263607)
10. Ali A, Zein NN. Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med. 2005;72(11):1005-1008, 1010-1014, 1016 passim.
11. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol. 1992;15(3):382-386.
12. Conca P, Tarantino G. Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. World J Gastroenterol. 2009;15(19):2305-2308.
13. Riccio A, Postiglione L, La Dogana P, Spanò A, Marzocchella C, Tarantino G. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents. 2008;22(1):57-61. (Pubitemid 351577893)
14. Riccio A, Postiglione L, Sabatini P, et al. Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study. Int J Immunopathol Pharmacol. 2012;25(1):281-285.
15. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol. 2008;21(6):813-825.
16. Ramos-Casals M, Jara LJ, Medina F, et al; HISPAMEC Study Group. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med. 2005;257(6):549-557. (Pubitemid 40776515)
17. Rivera J, García-Monforte A, Pineda A, Millán Núñez-Cortés J. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol. 1999;26(2):420-424. (Pubitemid 29066749)
18. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum. 1998;28(2):107-113. (Pubitemid 28480895)
19. Giannitti C, Bellisai F, Ferri C, Galeazzi M. Treatment strategies for a patient with rheumatoid arthritis and hepatitis C. Expert Opin Pharmacother. 2009;10(4):579-587.
20. Poantǎ L, Albu A. Chronic hepatitis C with extrahepatic manifestations. Rom J Intern Med. 2007;45(1):85-88.
21. Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol. 2000;18(5):579-584.
22. Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am. 2003;29(1):111-122. (Pubitemid 36298106)
23. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am. 2009;35(1):111-123.
24. Ezzat WM, Raslan HM, Aly AA, Emara NA, El Menyawi MM, Edrees A. Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. Rheumatol Int. 2011;31(1):65-69.
25. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21(3):613-619.
26. Ogdie A, Schumacher HR Jr, Dai L, Chen LX, Einhorn E, Pessler F. Synovial biopsy findings in arthritis associated with hepatitis C virus infection. J Rheumatol. 2010;37(6):1361-1363.
27. Rosner I, Rozenbaum M, Toubi E, Kessel A, Naschitz JE, Zuckerman E. The case for hepatitis C arthritis. Semin Arthritis Rheum. 2004;33(6):375-387. (Pubitemid 38887137)
28. Sène D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome. Ann Rheum Dis. 2006;65(3):394-397. (Pubitemid 43268232)
29. Amri M, Sfar I, Ounallah HS, et al. Anti-CCP antibodies, rheumatoid factors and anti-keratin antibodies: clinical value in established rheumatoid arthritis. Tunis Med. 2011;89(3):231-235.
30. Harris ED. Clinical features of rheumatoid arthritis. In: Harris ED, Budd RC, Firestein GS, et al. Kelly's Textbook of Rheumatology. vol II. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:1043-1100.
31. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 2003;139(3):234-235. (Pubitemid 38124610)
32. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 2002;60(10):383-388. (Pubitemid 39089354)
33. Palazzi C, Buskila D, D'Angelo S, D'Amico E, Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev. 2012;11(9):659-663.
34. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 2004;50(7):2305-2308. (Pubitemid 38924410)
35. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. (Pubitemid 351650500)
36. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273-281. (Pubitemid 28058927)
37. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155-163. (Pubitemid 30368225)
38. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000;43(8):1831-1835.
39. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46(2):357-365. (Pubitemid 34136572)
40. Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol. 2000;12(1):53-60. (Pubitemid 30036688)
41. Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008;26(1 suppl 48):S39-S47. (Pubitemid 351578094)
42. Kemmer NM, Sherman KE. Hepatitis C-related arthropathy: diagnostic and treatment considerations. J Musculoskelet Med. 2010;27(9):351-354.
43. Iagnocco A, Coari G, Mammarella A, et al. Joint sonography in asymptomatic patients with HCV correlated hepatitis. Clin Exp Rheumatol. 2004;22(1):43-48. (Pubitemid 38232808)
44. Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811-815. (Pubitemid 47266713)
45. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15(2):107-109. (Pubitemid 40434638)
46. Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy. 2005;51(2-3):167-169. (Pubitemid 40981076)
47. Johnson AE, Gordon C, Hobbs FD, Bacon PA. Undiagnosed systemic lupus erythematosus in the community. Lancet. 1996;347(8998):367-369. (Pubitemid 26046105)
48. Gourley IS, Patterson CC, Bell AL. The prevalence of systemic lupus erythematosus in Northern Ireland. Lupus. 1997;6(4):399-403. (Pubitemid 27232136)
49. Ramos-Casals M, Font J, García-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum. 2000;43(12):2801-2806. (Pubitemid 32001747)
50. Marchesoni A, Battafarano N, Podico M, Tosi S. Hepatitis C virus antibodies and systemic lupus erythematosus [letter]. Clin Exp Rheumatol. 1995;13(2):267.
51. Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am. 1995;21(1):81-98.
52. Mohan P, Rajasekaran M, Ramanathan P, Venkataraman J. Prevalence of hepatitis C virus antibodies in systemic lupus erythematosus. Eur J Gastroenterol Hepatol. 2009;21(12):1437-1438.
53. Ahmed MM, Berney SM, Wolf RE, et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci. 2006;331(5):252-256. (Pubitemid 43804602)
54. Mercado U, Avendaño-Reyes M, Araiza-Casillas R, Díaz-Molina R. Prevalance of antibodies against hepatitis C and B viruses in patients with systemic lupus erythematosus [in Spanish]. Rev Gastroenterol Mex. 2005;70(4):399-401.
55. El Garf A, El Zorkany B, Gheith R, Sheba H, Abdel Moneim G, El Garf K. Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward. Rheumatol Int. 2012;32(9):2691-2695.
56. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum. 1997;26(4):689-701. (Pubitemid 27118536)
57. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 1995;122(3):169-173.
58. Sansonno D, Carbone A, De Re V, Dammacco F. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford). 2007;46(4):572-578. (Pubitemid 46523298)
59. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035-1045.
60. Karakoç Y, Dilek K, Güllülü M, et al. Prevalence of hepatitis C virus antibody in patients with systemic lupus erythematosus. Ann Rheum Dis. 1997;56(9):570-571.
61. Lormeau C, Falgarone G, Roulot D, Boissier MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine. 2006;73(6):633-638. (Pubitemid 44918422)
62. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol. 1999;31(suppl 1):39-42. (Pubitemid 30002689)
63. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol. 1997;92(1):3-17.
64. Andrade LJ, D'Oliveira A Jr, Silva CA, et al. A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis. Acta Gastroenterol Latinoam. 2011;41(2):104-110.
65. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32(3):163-173. (Pubitemid 36043715)
66. Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol. 1992;65(1):70-74.
67. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24(2):178-181. (Pubitemid 40552976)
68. Rizvi R, Hojjati M. Interferon-α induced lupus in a patient with chronic hepatitis C virus. J Clin Rheumatol. 2011;17(3):152-153.
69. Lauletta G, Russi S, Conteduca V, Sansonno L. Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:502156.
70. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
71. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994;84(9):3047-3053. (Pubitemid 24328097)
72. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992;117(7):573-577.
73. Vermeersch P, Gijbels K, Mariën G, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem. 2008;54(1):39-43. (Pubitemid 351182594)
74. Wintrobe M, Buell M. Hyperproteinemia associated with multiple myeloma. With report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease. Bull Johns Hopkins Hosp. 1933;52:156-165.
75. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40(6):837-856.
76. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788.
77. Levo Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med. 1977;296(26):1501-1504. (Pubitemid 8140562)
78. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol. 1991;9(6):621-624.
79. Tissot JD, Schifferli JA, Hochstrasser DF, et al. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods. 1994;173(1):63-75. (Pubitemid 24249907)
80. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest. 2001;31(7):628-638. (Pubitemid 32642895)
81. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5(4):227-236. (Pubitemid 40410068)
82. De Vita S. Treatment of mixed cryoglobulinemia: a rheumatology perspective. Clin Exp Rheumatol. 2011;29(1 suppl 64):S99-S103.
83. Dammacco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol. 1992;87(3):352-356.
84. Saadoun D, Asselah T, Resche-Rigon M, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology. 2006;43(6):1337-1345. (Pubitemid 43980113)
85. Sansonno D, Tucci FA, Ghebrehiwet B, et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol. 2009;183(9):6013-6020.
86. Ferri C, Sebastiani M, Antonelli A, Colaci M, Manfredi A, Giuggioli D. Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther. 2012;14(3):215.
87. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
88. Ramos-Casals M, Brito-Zerón P, Font J. Lessons from diseases mimicking Sjögren's syndrome. Clin Rev Allergy Immunol. 2007;32(3):275-283. (Pubitemid 350242573)
89. Ramos-Casals M, Muñoz S, Zerón PB. Hepatitis C virus and Sjögren's syndrome: trigger or mimic? Rheum Dis Clin North Am. 2008;34(4):869-884, vii.
90. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19(4):841-848. (Pubitemid 24109343)
91. Loustaud-Ratti V, Riche A, Liozon E, et al. Prevalence and characteristics of Sjögren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: a prospective study. J Rheumatol. 2001;28(10):2245-2251. (Pubitemid 32947870)
92. Madaliński K, Godzik P, Zimmermann-Górska I, et al. Anti-HCV and HCV RNA in patients with the primary Sjögren syndrome [in Polish]. Przegl Epidemiol. 2009;63(2):299-304.
93. Baldini C, Talarico R, Tzioufas AG, Bombardieri S. Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun. 2012;39(1-2):9-14.
94. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol. 2005;17(4):447-455. (Pubitemid 41058405)
95. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore). 2005;84(2):81-89. (Pubitemid 40418636)
96. Ramos-Casals M, Theander E, Tzioufas AG, et al. Digestive involvement in primary Sjogren syndrome. In: Font J, Ramos-Casals M, Rodes J, et al, eds. Digestive Involvement of Autoimmune Diseases. Amsterdam, The Netherlands: Elsevier; 2008:71-81.
97. Valente RM, Conn DL. Current therapies for systemic vasculitis. Semin Neurol. 1994;14(4):380-386.
98. Talarico R, Baldini C, Della Rossa A, et al. Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol. 2012;30(1 suppl 70):S130-S138.
99. Pagnoux C, Seror R, Henegar C, et al French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616-626.
100. Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken). 2011;63(3):427-435.
101. Soufir N, Descamps V, Crickx B, et al. Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch Dermatol. 1999;135(8):1001-1002. (Pubitemid 29382456)
102. Cacoub P, Maisonobe T, Thibault V, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol. 2001;28(1):109-118. (Pubitemid 32062032)
103. de Menthon M, Mahr A. Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol. 2011;29(1 suppl 64):S110-S116.
104. Culver DA. Sarcoidosis. Immunol Allergy Clin North Am. 2012;32(4):487-511.
105. Ramos-Casals M, Mañá J, Nardi N, et al; HISPAMEC Study Group. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore). 2005;84(2):69-80. (Pubitemid 40418635)
106. Jadali Z. Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy: a literature review. Arch Iran Med. 2012;15(1):43-48.
107. Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med. 2003;14(4):237-243. (Pubitemid 36952702)